Correspondence 0001213900-25-008323 from OSR Health, Inc. (OSRH)
OSR Health, Inc.
Date: Jan. 30, 2025 · CIK: 0001840425 · Accession: 0001213900-25-008323
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280590
Letter
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
10900 NE 4th Street, Suite 2300
Bellevue, WA 98004
January 30, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attn: Kristin Lochhead
Li Xiao
Juan Grana
Katherine Bagley
Re: Registration Statement on Form S-4
File No.: 333-280590
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), Bellevue Life Sciences Acquisition Corp. (the “Company”) hereby requests the Securities and Exchange Commission to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) and declare the Registration Statement effective under the Securities Act at 4:00 p.m., Eastern Time, on Friday, January 31, 2025, or as soon thereafter as practicable. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Securities Act.
If there is any change in the acceleration request set forth above, the Company will promptly notify you of the change, in which case the Company may make an oral request of acceleration of the effectiveness of the Registration Statement in accordance with Rule 461 of Regulation C. Such request may be made by an executive officer of the Company or by any attorney from the Company’s U.S. counsel, K&L Gates LLP.
[Signature Page Follows]
Thank you for your assistance in this matter.
Sincerely,
Bellevue Life Sciences Acquisition Corp.
Show Raw Text
CORRESP
1
filename1.htm
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
10900 NE 4th Street, Suite 2300
Bellevue, WA 98004
January 30, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attn:
Kristin Lochhead
Li Xiao
Juan Grana
Katherine Bagley
Re:
Registration Statement on Form S-4
File No.: 333-280590
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 under
the Securities Act of 1933, as amended (the “Securities Act”), Bellevue Life Sciences Acquisition Corp. (the “Company”)
hereby requests the Securities and Exchange Commission to accelerate the effective date of the above-referenced registration statement
(the “Registration Statement”) and declare the Registration Statement effective under the Securities Act at 4:00 p.m., Eastern
Time, on Friday, January 31, 2025, or as soon thereafter as practicable. In making this acceleration request, the Company acknowledges
that it is aware of its responsibilities under the Securities Act.
If there is any change in the acceleration request set
forth above, the Company will promptly notify you of the change, in which case the Company may make an oral request of acceleration of the
effectiveness of the Registration Statement in accordance with Rule 461 of Regulation C. Such request may
be made by an executive officer of the Company or by any attorney from the Company’s U.S. counsel, K&L Gates LLP.
[Signature Page Follows]
Thank you for your assistance in this matter.
Sincerely,
Bellevue Life Sciences Acquisition Corp.
By:
/s/ Kuk Hyoun Hwang
Name:
Kuk Hyoun Hwang
Title:
Chief Executive Officer